{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:22:59Z","timestamp":1787743379672,"version":"build-2784847793"},"reference-count":40,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Transplantation"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alemtuzumab is an induction immunosuppressive agent effective in preventing hyperacute rejection; however, it can result in prolonged lymphocyte depletion. Here we assessed the dosing, tolerability, and outcomes with alemtuzumab induction via IV vs. SQ route in pediatric kidney transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A multicenter analysis of 119 patients &lt;\u200921\u2009years old who received alemtuzumab induction immunosuppression. Total dose (mg) and dose by body weight (mg\/kg) were assessed. Tolerability was defined by the development of leukopenia (WBC &lt;\u20093.0 \u00d7\u200910\n                      <jats:sup>3<\/jats:sup>\n                      \/uL) or neutropenia (ANC &lt;\u20091.5 \u00d7\u200910\n                      <jats:sup>3<\/jats:sup>\n                      \/uL). Outcomes in the first year post\u2010transplant were defined by eGFR, hospitalizations, infections, development of\n                      <jats:italic>de novo<\/jats:italic>\n                      DSA, and rejection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 83 and 36 recipients received alemtuzumab IV and SQ, respectively. SQ group was slightly older, 14.0\u2009y. (SD 5.5) vs. 11.9\u2009y. (SD 6.1) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.07), and had more highly sensitized recipients, 14 (38.9%) vs. 10 (12.1%) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). Total dose and dose by weight were higher in the SQ group, 22.3\u2009mg (SD 8.9) vs. 14.9\u2009mg (SD 9.5), and 0.57\u2009mg\/kg (SD 0.21) vs. 0.36\u2009mg\/kg (SD 0.18\u2009mg), respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0001 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). SQ group experienced more leukopenia and resultant medication dose reduction; however, there were no differences between the groups in eGFR, infections, hospitalizations, and rejection in the year following transplant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the higher dose of alemtuzumab and rates of leukopenia in the SQ group, there were no other differences in tolerability and outcomes compared to IV alemtuzumab. Overall, alemtuzumab is well tolerated during the first year post\u2010transplant as an induction immunosuppression agent in the pediatric population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/petr.70424","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:29:27Z","timestamp":1786606167000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alemtuzumab Induction via Intravenous vs. Subcutaneous Administration in Pediatric Kidney Transplantation"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2997-7483","authenticated-orcid":false,"given":"H.","family":"Pizzo","sequence":"first","affiliation":[{"name":"Pediatric Nephrology Cedars\u2010Sinai Guerin Children's  Los Angeles USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0137-2916","authenticated-orcid":false,"given":"A.","family":"Barbera","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Heersink School of Medicine, University of Alabama at Birmingham  Birmingham USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7208-2378","authenticated-orcid":false,"given":"K.","family":"Westreich","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology University of North Carolina  Chapel Hill USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0557-6178","authenticated-orcid":false,"given":"M. E.","family":"Seifert","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Heersink School of Medicine, University of Alabama at Birmingham  Birmingham USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2338-193X","authenticated-orcid":false,"given":"J.","family":"Mirocha","sequence":"additional","affiliation":[{"name":"Biostatistics Core, Research Institute Cedars\u2010Sinai Medical Center  Los Angeles USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kirshner","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Cedars\u2010Sinai Guerin Children's  Los Angeles USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6988-8533","authenticated-orcid":false,"given":"D.","family":"Puliyanda","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Cedars\u2010Sinai Guerin Children's  Los Angeles USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010017\u20100573\u2010x"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15608"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000071362.99021.D9"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009546"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001416"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13685"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011040360"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2023.11834"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2011.07.002"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14753"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432\u20102277.2012.01448.x"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2014.07.070"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2008.02.048"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13775"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14783"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20106143.2007.02017.x"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0897190019850934"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2004.06.015"},{"key":"e_1_2_11_20_1","unstructured":"Laboratories B \u201cAlemtuzumab [package insert]. FDA\/Center for Drug Evaluation and Research2001\u201d."},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102004\u201002\u20100593"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102974"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2025.102179"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.10.022"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20106143.2008.02528.x"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.047"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14173"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12253"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12159"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.01.008"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181903da7"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1605794"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12978"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399\u20100012.2008.00893.x"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002762"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12048"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691\u2010200002000\u201000003"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1188\/19.ONF.E38\u2010E47"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467\u2010023\u201005955\u20105"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13925"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13928"}],"container-title":["Pediatric Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/petr.70424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/petr.70424","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/petr.70424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:58:05Z","timestamp":1787741885000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/petr.70424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/petr.70424"],"URL":"https:\/\/doi.org\/10.1111\/petr.70424","archive":["Portico"],"relation":{},"ISSN":["1397-3142","1399-3046"],"issn-type":[{"value":"1397-3142","type":"print"},{"value":"1399-3046","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2026-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70424"}}